Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Vertex Pharmaceuticals, Inc shares valued at $7,178 were sold by ALTSHULER DAVID on Nov 15 ’24. At $478.56 per share, ALTSHULER DAVID sold 15 shares. The insider’s holdings dropped to 25,813 shares worth approximately $10.54 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, ALTSHULER DAVID purchased 15 shares, netting a total of over 7,178 in proceeds.
Before that, WAGNER CHARLES F JR had sold 3,000 shares from its account. In a trade valued at $1,554,810, the EVP & Chief Financial Officer traded Vertex Pharmaceuticals, Inc shares for $518.27 each. Upon closing the transaction, the insider’s holdings decreased to 3,000 shares, worth approximately $18.02 million.
As published in a research note from H.C. Wainwright on December 20, 2024, Vertex Pharmaceuticals, Inc [VRTX] has been retained to a Buy and the price target has been revised to $535. Analysts at Oppenheimer downgraded the stock from ‘”an Outperform”‘ to ‘”a Perform”‘ outlook in a report released in mid December. As of December 09, 2024, Jefferies has increased its “Hold” rating to a “Buy” for VRTX. Earlier on November 14, 2024, Citigroup initiated its rating. Their recommendation was “a Buy” for VRTX stock.
Analyzing VRTX Stock Performance
During the last five days, there has been a drop of approximately -13.07%. Over the course of the year, Vertex Pharmaceuticals, Inc shares have jumped approximately 0.25%. Shares of the company reached a 52-week high of $519.88 on 11/08/24 and a 52-week low of $377.85 on 12/19/24. A 50-day SMA is recorded $467.71, while a 200-day SMA reached $457.57. Nevertheless, trading volume fell to 1.47 million shares from 2.19 million shares the previous day.
Support And Resistance Levels for Vertex Pharmaceuticals, Inc (VRTX)
According to the 24-hour chart, there is a support level at 402.74, which, if violated, would cause prices to drop to 397.30. In the upper region, resistance lies at 412.15. The next price resistance is at 416.12. RSI (Relative Strength Index) is 30.60 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -43.11, which suggests the price will decrease in the coming days. Percent R is at 69.24%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
